-+ 0.00%
-+ 0.00%
-+ 0.00%

REPLIMUNE GROUP - TO RESUBMIT RP1 BLA FOR ADVANCED MELANOMA AFTER ALIGNMENT WITH FDA

Reuters·05/29/2026 12:00:02

Please log in to view news